We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Atkins Plus KetoCal for Childhood Epilepsy

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: May 21, 2008
Last Update Posted: December 31, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Nutricia, Inc.
Information provided by:
Johns Hopkins University
The modified Atkins diet (MAD) is a relatively new, alternative dietary therapy for intractable childhood and adult epilepsy. Recent evidence suggests that a strict, highly ketotic, first month may be advantageous to both immediate and long-term efficacy. KetoCal® is a pre-mixed powder that can be used to create a 4:1 ketogenic diet shake as a meal substitute. The investigators hypothesize that substituting KetoCal® for a lunch during the initial month of the MAD will lead to improved seizure reduction over the MAD alone, as well as improved tolerability and lipid values.

Condition Intervention Phase
Epilepsy Dietary Supplement: Modified Atkins diet and KetoCal Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Evaluation of KetoCal in Initial Combination With the Modified Atkins Diet for the Treatment of Intractable Childhood Epilepsy

Resource links provided by NLM:

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Seizure reduction [ Time Frame: 2 months ]

Secondary Outcome Measures:
  • Ketosis [ Time Frame: 2 months ]
  • Tolerability and taste [ Time Frame: 2 months ]

Estimated Enrollment: 30
Study Start Date: May 2008
Study Completion Date: December 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Patients will receive the modified Atkins diet in combination with a 10 oz KetoCal shake for the first month. The second month no shake will be given. Results at 1 month will be compared to 2 months, as well as to historical controls with the modified Atkins diet.
Dietary Supplement: Modified Atkins diet and KetoCal
10 gram per day Modified Atkins diet and 10 oz per day of KetoCal shake.
Other Name: KetoCal

  Show Detailed Description


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   3 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children ages 3-17 years
  • At least daily seizures (or 7 per week). All seizure types allowed
  • Tried at least two anticonvulsants

Exclusion Criteria:

  • Unwilling to restrict carbohydrates
  • Significantly underweight (BMI ≤ 5%)
  • Prior use of the modified Atkins diet for ≥ 2 days
  • Prior use of KetoCal® at any time for any duration
  • Use of the KD within the past year
  • Kidney disease
  • History of hypercholesterolemia(>300 mg/dl) or hypertriglyceridemia (>200 mg/dl)
  • Metabolic or mitochondrial disorder
  • Aversion to shakes or inability to eat solid food
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00681239

United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Johns Hopkins University
Nutricia, Inc.
Principal Investigator: Eric H Kossoff, MD Johns Hopkins University
  More Information

Responsible Party: Eric Kossoff MD, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00681239     History of Changes
Other Study ID Numbers: NA_00017953
First Submitted: May 19, 2008
First Posted: May 21, 2008
Last Update Posted: December 31, 2009
Last Verified: December 2009

Keywords provided by Johns Hopkins University:

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases